The Thymoma (Thymic Epithelial Tumor) drugs in development market research report provides comprehensive information on the therapeutics under development for Thymoma (Thymic Epithelial Tumor), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Thymoma (Thymic Epithelial Tumor). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thymoma (Thymic Epithelial Tumor) and features dormant and discontinued products.

GlobalData tracks 50 drugs in development for Thymoma (Thymic Epithelial Tumor) by 43 companies/universities/institutes. The top development phase for Thymoma (Thymic Epithelial Tumor) is phase ii with 33 drugs in that stage. The Thymoma (Thymic Epithelial Tumor) pipeline has 48 drugs in development by companies and two by universities/ institutes. Some of the companies in the Thymoma (Thymic Epithelial Tumor) pipeline products market are: SciClone Pharmaceuticals, Merck and Pfizer.

The key targets in the Thymoma (Thymic Epithelial Tumor) pipeline products market include Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC, Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274).

The key mechanisms of action in the Thymoma (Thymic Epithelial Tumor) pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with six drugs in Phase II. The Thymoma (Thymic Epithelial Tumor) pipeline products include ten routes of administration with the top ROA being Intravenous and eight key molecule types in the Thymoma (Thymic Epithelial Tumor) pipeline products market including Small Molecule, and Monoclonal Antibody.

Thymoma (Thymic Epithelial Tumor) overview

Thymoma, also known as thymic epithelial tumor, is a rare type of cancer that originates in the thymus gland, a small organ located behind the breastbone and in front of the heart. The thymus gland plays a role in the development of certain immune cells and is most active during childhood but gradually becomes less active with age. Thymomas are categorized based on their microscopic appearance and cell characteristics. They are classified into various subtypes, and the World Health Organization (WHO) system categorizes them into different stages (from Type A to Type AB, B1, B2, B3, and thymic carcinoma). The exact cause of thymoma is unknown. It is believed that genetic mutations or alterations in the cells of the thymus gland may contribute to the development of these tumors. Thymomas are sometimes associated with autoimmune disorders, such as myasthenia gravis, but the relationship between the two conditions is not fully understood. Thymomas often do not cause symptoms in the early stages. As the tumor grows, it may cause chest pain or pressure, coughing or difficulty breathing, shortness of breath, recurrent respiratory infections, or myasthenia gravis symptoms in some cases, including muscle weakness, drooping eyelids, and difficulty swallowing or speaking.

For a complete picture of Thymoma (Thymic Epithelial Tumor)’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.